Search results
Biophytis Announces Filing of an IND Application with the US FDA for its Phase 2 Study in Obesity
Digital Journal· 1 day agoParis:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announces that it has submitted ...
Truth or Myth: Will the ‘Hair of the Dog’ Fix Your Hangover? Experts Explain
Prevention· 7 days agoYou’ve likely heard hangover cures involving “the hair of the dog that bit you,” or that greasy food...
CG Oncology reports promising bladder cancer trial results By Investing.com
Investing.com· 5 days agoCG Oncology, Inc. (NASDAQ: CGON), a biopharmaceutical company engaged in the development of oncology...
Arcturus reports positive ARCT-032 cystic fibrosis data By Investing.com
Investing.com· 4 days agoArcturus Therapeutics (NASDAQ:ARCT) Holdings Inc. (NASDAQ: ARCT), a biotechnology company...
Hanesbrands stock looks ripe for rally after nine-year slump
The Forex Market· 7 days agoHanesbrands stock has recently made a new range high. HBI stock has been trending downward for most...
Insider Selling: McKesson Co. (NYSE:MCK) CEO Sells 3,753 Shares of Stock
ETF DAILY NEWS· 4 days agoMcKesson Co. (NYSE:MCK – Get Free Report) CEO Brian S. Tyler sold 3,753 shares of McKesson stock in a transaction that occurred on Wednesday, June 5th. Following the sale, the chief executive ...
Combined General Meeting of June 24, 2024
Digital Journal· 4 days agoBIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular (sarcopenia, phase 3 ready and Duchenne muscular dystrophy), respiratory ...
McKesson Co. (NYSE:MCK) Shares Sold by Cetera Advisor Networks LLC
ETF DAILY NEWS· 2 days agoCetera Advisor Networks LLC cut its holdings in McKesson Co. (NYSE:MCK – Free Report) by 9.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 15,517 ...
